The solubility of a drug is a key parameter that influences its ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. Traditional strategies to affect solubility have focused on salt formation and medicinal chemistry approaches that rely on organic transformations of the parent compound. The importance of searching for and selecting a particular polymorph is also an important strategy that has been recently developed. More recently, the concept of supramolecular synthesis has been applied to generate multiple component crystals (i.e. co-crystals), which exhibit distinctive solubility properties with respect to the pure form. This study presents an alternate, complementary strategy to affect solubility: the synthesis of mixed ligand transition metal coordination complexes. To date, transition metals in medicine have found a place in metal-based drugs and metal-based diagnostic agents such as contrast agents for MRI and radiopharmaceuticals. In these materials, the utility is derived from the properties of the metal. In contrast, this study focuses on transition metal complexes in which the active species is a ligand. For example, compounds containing non-steroidal anti-inflammatory drugs (NSAIDs) as ligands in copper(ii) complexes are known; indeed, they have been shown to exhibit both enhanced efficacy and reduced side-effects. This presentation will describe how the judicious choice of an ancillary ligand affords the ability to control the solubility of such complexes. Specifically, aspirin and salsalate and a representative group of ancillary ligands were selected to form congeneric series of mixed ligand copper(ii) coordination species, which exhibit dramatically different partition coefficients (LogP), and solubilities in octanol and water.